Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health discusses the future of clinical trials and how the software tool, OncoTrials, can be used to help match patients to trials.
Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health discusses the future of clinical trials and how the software tool, OncoTrials, can be used to help match patients to trials.
What do clinical trials of the future look like? Is it using surrogate endpoints? Or some other change?
It’s a whole host of things. So, in the example of what’s called a pragmatic clinical trial, you can try to reflect real-world care in the design of an interventional trial, and instead of having traditional endpoints, like resist criteria which is a very rigid way of measuring whether a tumor responds; the goal is to come up with endpoints using real-world data that can effectively substitute from some of the more traditional endpoints that we often use and think about.
How is technology helping to get patients, especially those treated at community oncology practices, considered for clinical trials?
There are a number of ways that you can try to make recruitment better. One of the main approaches that we’ve taken is a software tool called OncoTrials. OncoTrials is almost like an electronic medical record, but not for doctors, but for research coordinators—the people who work in a practice trying to identify patients for trials. It helps them go through the incredibly large volume of patients who come into an oncology clinic a day. It’s a number that’s really too big to effectively look at and try to identify patients for trials, and to limit that list down to only the patients who you need to be looking at on that given day. It’s a tool that we found that has made research coordinators much more efficient and enabled them to find more patients for clinical trials. We do think, however, that there are multiple other ways that you can do this; a perfect example is in biomarker driven studies. So, typically patients who have unusual biomarkers are hard to identify for clinical trials. Why? The biomarker may be something that a Doc’s not familiar with and they may not even know that a clinical trial is open at their site or somewhere else. The information often gets buried in the chart and people don’t think about it. We think there’s a great opportunity in other ways to try to match more patients to clinical trials. But, we’re very early in the process, and when I say we, I mean the community in general.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More